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Rapport de synthèse 
Contexte 
L'hyperthyroïdie infra-clinique est une perturbation de la fonction thyroïdienne, définie par 
une thyrotropine (TSH} basse et des taux normaux de thyroxine libre (T4L} et 
triiodothyronine (T3}. Cette dysfonction affecte de 1% à 5% des adultes de plus de 65 ans, 
surtout les femmes, et pourrait être associée avec les maladies cardiovasculaires, la 
fibrillation auriculaire et l'insuffisance cardiaque. Toutefois, les conclusions des différentes 
études de cohortes sont contradictoires, avec des limites méthodologiques empêchant leur 
comparaison de manière formelle. L'objet du travail de thèse était d'estimer le risque de 
mortalité de toute cause, le risque de mortalité de cause cardiovasculaire, le risque 
d'événements cardiovasculaires et le risque de fibrillation auriculaire associés à 
l'hyperthyroïdie infra-clinique dans toutes les grandes études de cohorte prospectives 
disponibles à ce jour. 
Méthode et Résultats 
Les données individuelles de 52'674 participants provenant de 10 études de cohorte 
prospectives des Etats-Unis, d'Europe, du Brésil et d'Australie ont été analysées pour évaluer 
les risques à long-terme de l'hyperthyroïdie infra-clinique. L'euthyroïdie était définie par une 
TSH entre 0.45 et 4.49 mUl/I et l'hyperthyroïdie infra-clinique par une TSH inférieure à 0.45 
mUl/I avec un taux normal de T4L, après exclusion des participants prenant des médicaments 
pouvant perturber la thyroïde. 
Sur les 52'674 participants, 2188 (4.2%} avaient une hyperthyroïdie infra-clinique. Pendant 
un suivi de plus de 8 ans, 8527 participants sont décédés (dont 1896 de cause 
cardiovasculaire), 3653 sur 22'437 ont eu un événement cardiovasculaire et 785 sur 8711 ont 
développé une fibrillation auriculaire. Dans des analyses ajustées pour l'âge et le sexe, 
l'hyperthyroïdie infra-clinique était associée à une hausse de la mortalité de toute cause 
(hazard ratio [HR] 1.24, intervalle de confiance à 95% [IC] 1.06-1.46}, de la mortalité 
cardiovasculaire (HR 1.29, IC 1.02-1.62}, des événements cardiovasculaires (HR 1.21, IC 0.99-
1.46} ainsi qu'une hausse de l'incidence de fibrillation auriculaire (HR 1.68, IC 1.16-2.43}. Les 
risques ne différaient pas significativement dans les analyses stratifiées selon l'âge, le sexe ou 
la présence de maladies cardiovasculaires préexistantes, et étaient similaires après 
ajustement multiple pour les facteurs de risque cardiovasculaire. Le risque de mortalité 
cardiovasculaire et de fibrillation auriculaire était plus élevé avec une TSH très basse(< 0.10 
Ul/I) comparé à une TSH modérément abaissée (0.10-0.44 mUl/I, valeurs p for trend::; 0.03). 
Conclusions et perspectives 
L'hyperthyroïdie infra-clinique est associée à un risque augmenté de mortalité de toute 
cause, de cause cardiovasculaire et de fibrillation auriculaire, avec un risque plus élevé quand 
la TSH est inférieure à 0.10 mUl/I. Ces résultats sont cohérents avec les dernières 
recommandations internationales conseillant de considérer un traitement de 
l'hyperthyroïdie infra-clinique pour les adultes de plus de 65 ans ou les patients avec maladie 
cardiaque, en particulier si la TSH est inférieure à 0.10 mlJl/I. Toutefois, des études cliniques 
randomisées sont encore nécessaires pour prouver l'efficacité du traitement et déterminer si 
l'on devrait dépister les problèmes de thyroïde dans la population générale. 
Lausanne, le 31 juillet 2012 
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Background: Data from prospective cohort studies re-
garding the association between subclinical hyperthyroid-
ism and cardiovascular outcomes are conflicting. We aimed 
to assess the risks of total and coronary heart disease ( CHD) 
mortality, CHD events, and atrial fibrillation (AF) associ-
ated with endogenous subclinical hyperthyroidism among 
all available large prospective cohorts. 
Methods: Individual data on 52 674 participants were 
pooled from 10 cohorts. Coronary heart disease events were 
analyzed in 22 437 participants from 6 cohorts with avail-
able data, and incident AF was analyzed in 8711 partici-
pants from 5 cohorts. Euthyroidism was definecl as thyro-
tropin level between 0.45 and 4.49 mIU/L and endogenous 
subclinical hyperthyroidism as thyrotropin level lower than 
0.45 mIU/L with normal free thyroxine levels, after ex-
cluding those receiving thyroicl-altering medications. 
Results: Of 52 674 participants, 2188 ( 4.2%) had sub-
clinical hyperthyroidism. During follow-up, 8527 par-
ticipants died (including 1896 from CHD), 3653 of 22 4 3 7 
had CHD events, and 785 of 8711 developed AF. In age-
and sex-adjusted analyses, subclinical hyperthyroidism 
was associated with increased total mortality (hazard ra-
tio [HR), 1.24, 95% CI, 1.06-1.46), CHD mortality (HR, 
1.29; 95% CI, 1.02-1.62), CHD events (HR, 1.21; 95% 
CI, 0.99-1.46), and AF (HR, 1.68; 95% CI,,l.16-2.43). 
Risks did not differ significantly by age, sex, or preex-
isting cardiovascular disease and were similar after fur-
ther acljustment for cardiovascular risk factors, with at-
tributable risk of 14 .5% for total mortality to 41.5% for 
AF in those with subdinical hyperthyroidism. Risks for 
CHD mortality and AF (but not other outcomes) were 
higher for thyrotropin level lower than 0.10 mIU/L com-
pared with thyrotropin level between 0.10 and 0.44 mIU/L 
(for both, P value for trend, :S.03). 
Conclusion: Endogenous subclinical hyperthyroidism is 
associated with increased risks of total, CHD mortality, and 
incident AF, with highest risks of CHD mortality and AF 
when thyrotropin level is lower than 0.10 mIU/L. 
Arcl1 Intem Med. 2012;172(10):799-809. 
Published online Ap1il 23, 2012. 
doi: 10.1001/archintemmed.2012. 402 
UBCLINICAL HYPERTHYROID-
ism, defined by low thyrotro-
pin level with normal concen-
trations offree thyroxine (FT4) 
and triiodothyronine (T 3), 1·4 
tion. 13•14 Results from prospective cohort 
studies are conflicting,6·10 and study-
level meta-analyses have reached contra-
dictory conclusions, for example, regard-
ing the association between subclinical 
hyperthyroidism and cardiovascular mor-
tality.15·17 In fact, interpretation of these 
studies is hampered by several method-
ological factors: population heteroge-
neity, different thyrotropin cutofflevels for 
Author Affiliations are listed at 
the end of this article. 
Group Information: 
Participating studies of the 
Thyroid Stuclies Collaboration 
are listed at the end of the 
artiçle. 
has been associated with several biological 
effects on cardiovascular system, such as in-
creased heart rate, left ventricular mass, ca-
rotid intima-media thickness, and plasma 
fibrinogen levels.3-5 Observational studies 
See Invited Commentary 
at end of article 
have reported an association between 
subclinical hyperthyroidism and coro-
nary heart disease ( CHD), 5-s incident a trial 
fibrillation (AF),9· 12 and cardiac dysfunc-
See also page 811 
subclinical hyperthyroidism definition, 
different use of covariates, and different 
CHD definitions.16 Although no large ran-
domized controlled trials have examined 
the effects of treating subclinical hyper-
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thyroidism on clinically relevant outcomes, a consen-
sus statement2 and recent guiclelines4 advocate treat-
ment of subclinical hyperthyroiclism, particularly when 
thyrotropin level is lower than 0.10 mlU/L, to avoid long-
term complications. 
Indiviclual participant data analysis from large cohort 
studies may help reconcile these conflicting results; allow 
exploration of the influence of age, sex, thyrotropin lev-
els, and preexisting cardiovascular disease (CVD); and al-
lows the use of a uniform thyrotropin cutoff level and out-
come definitions for all participants. This approach is 
considerecl optimal for synthesizing evidence across co-
horts because it is not subject to potential bias from study-
level meta-analyses (ecological fallacy) 18 and allows per-
formance of time-to-event analyses. 19 
On the basis of data from the Thyroicl Studies Col-
laboration,20 we aimecl to assess the risks of total mor-
tality, CHD mortality, CHD events, andAF associated with 
endogenous subclinical hyperthyroidism. 
Similar to our previous study,20 we conducted a systematic lit-
erature search in MEDLINE and EMBASE databases from 
1950 to June 30, 2011, without language restriction (eAppen-
dix; http://www.archinternmed.com), and screened bibliogra-
phies from retrieved articles. We used a priori criteria for greater 
comparability and quality of the studies. We included only full-
text published longitudinal cohorts reporting baseline thyroid 
function test results (both thyrotropin and FT 4), with a contrai 
euthyroid group and prospective follow-up of mortality and CHO 
outcomes. We excluded studies that included only participants 
taking thyroid-altering medications (antithyroid drugs, thyrox-
ine, or amiodarone) or participants with oven hyperthyroidism 
(low thyrotropin and high FT4 levels). We performed an addi-
tional systematic literature review for articles reporting inci-
dentAF events and updated our previous search20 tojune 2011. 
Reviews were perfonned independently by 2 authors (P.B. and 
B. G.), and discrepancies were resolved by discussion with a third 
author (N.R.). Agreement between reviewers was 99.9% for first 
screen (titles and abstracts, K= 0.66; 95% CI, 0.62-0. 72) and 100% 
for full-text screen (K= 1.00). 
Data were collected from original studies that joined the Thy-
roid Studies Collaboration20 and included individual demo-
graphic characteristics; thyrotropin, FT4, and total T3 or free 
T3 levels; baseline cardiovascular risk factors (eg, blood pres-
sure, cigarette smoking, total cholesterol level, diabetes melli-
tus); preexisting CVD; and cardiovascular and thyroid-
altering medication use at baseline and during follow-up. Data 
on mortality, CHO events, AF, stroke, and cancer outcomes were 
requested. 
Similar to our previous analysis,20 we used a uniform thy-
rotropin cutoff level for subclinical hyperthyroidism defini-
tion, based on an expert consensus meeting of our collabora-
tion 20 (International Thyroid Conference, Paris, France, 
2010), expert reviews, 1·21 and previous large cohorts. 10·22•23 
Subclinical hyperthyroidism was defined as a thyrotropin 
level lower than 0.45 m!U/L with normal FT4 levels, and 
euthyroidism as a thyrotropin level between 0.45 and 4.49 
mIU/L. Subclinical hyperthyroidism was further categorized 
as suppressed thyrotropin level (<0.10 mIU/L) and low but 
not suppressed thyrotropin level (0.10-0.44 mIU/L) according 
to current guidelines. 1·4 Data from cohorts using first-
generation thyrotropin assays (functional sensitivity, 1-2 
m!U/L) were excluded9·24•25 because subclinical hyperthyroid-
ism cannot be diagnosed using these methods. 26 For FT4 and 
total and free T3, we used study-specific cutoff values because 
these measurements show greater intermethod variation than 
thyrotropin assays. For participants with missing values of 
FT4 and total or free T3 (measured in 5of10 cohorts [eTable]), 
we performed sensitivity analyses excluding (1) participants with 
missing FT4 values and (2) those with abnormal total or free T3 
levels. H,21 
Outcomes were total mortality, CHO mortality, CHO 
events, and incident AF. Stroke and cancer mortality were 
available for al! cohorts except one. 27 As in our previous 
analysis,20 we used homogenous definitions to reduce the 
heterogeneity in outcomes. 15·16 Similar to the Framingham 
risk score, 28 we limited cardiovascular mortality to CHO 
mortality or sudden death (eTable). We defined CHO events 
as nonfatal myocardial infarction or CHO death (equivalent to 
hard events28) or hospitalization for angina or coronary revas-
cularization.10 We performed a sensitivity analysis with hard 
CHO events only (ie, CHO death, nonfatal myocardial infarc-
tion). For AF analyses, participants with baseline AF were ex-
cluded (eTable). 
To assess the risks of endogenous subclinical hyperthyroid-
ism, we excluded participants using thyroxine or antithyroid 
drugs at baseline. To explore the possible heterogeneity be-
tween exogenous (using thyroid-altering medications) and en-
dogenous subclinical hyperthyroidism, we performed sensi-
tivity analyses by adding participants using thyroxine or 
antithyroid drugs at baseline. 
We conducted a study quality evaluation using previous cri-
teria16 after collecting the following additional information from 
study authors: methods of outcome adjudication and ascer-
tainment, accounting for confounders, and completeness of 
follow-up. 
The association between subclinical hyperthyroidism and 
each outcome was analyzed using separate Cox proportional 
hazard models for each cohort (SAS 9.2 [SAS Institute !ne]; Stata 
11.2 [StataCorp]). Pooled estima tes for each outcome were cal-
culated using random-effects models based on inverse vari-
ance model29 as recommended. 19·30·31 Results were summa-
rized using forest plots (Review Manager 5.1.2, Nordic Cochrane 
Centre). To assess heterogeneity across studies, we used the 12 
statistic, which measures the inconsistency across studies at-
tributable to heterogeneity instead of chance alone.32 
Primary analyses were adjusted for age and sex (some tra-
ditional cardiovascular risk factors being potential media-
tors3), then further adjusted for traditional cardiovascular risk 
factors (systolic blood pressure, current or former smoking, total 
cholesterol, and diabetes). As missing data rates were lower than 
3% and unlikely to substantially bias the multivariate mode! 
estimates,33 complete case analysis was used. 
To explore potential sources ofheterogeneity, we perfonned 
predefined subgroup and sensitivity analyses, as in our previous 
analysis.20 We conducted stratified analyses byage, sex, race, thy-
rotropin categories, and preexisting CVD. For strata with par-
ticipants but no event in some subgroup analyses, we used pe-
nalized likelihood methods34 to calcula te hazard ratios (HRs) and 
95% confidence intervals. To calculate age- and sex-adjusted event 
rates/1000 person-years, we used Poisson models.35 We checked 
the proportional hazard assumption using graphical methods and 
the Schoenfeld test.36 For publication bias, we used age- and sex-
adjusted funnel plots and the Egger test.37 
Among iclentified reports, 13 prospective cohorts met all 
inclusion criteria (eFigure). We excluded 3 co-
horts9·24·25 using first-generation thyrotropin assays,26 
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Table 1. Baseline Characterislics of lndividuals in lncluded Studies 
No. ('Io) 
Thyroid Follow·upd 
Descriplion Age, Endogenous Medication 
of Study No. of Median Subclinical Du ring Duration, Persan· 
Source sample Participants (Range), ya Women Hyperthyroidism b Follow-upc Star! Median (IOR) years 
United States 
Cardiovascular Community-dwelling 2569 71 (64-100) 1516 (59.0) 43 (1.7) 57 (2.2) 1989-1990 14.0 (8.6-16.4) 31599 
Health adults with 
Study10 Medicare eligibility 
ln 4 US 
communities 
Health, ABC Community-dweliing 2212 74 (70-79) 1062 (48.0) 43 (1.9) 43 (1.9) 1997 8.1 (7.2-8.3) 15 772 
StudyM adultswith 
Mediéare eligibilîty 
ln 2US 
communities 
Europe 
Birmingham Community-dweliing 1075 69 (60-94) 586 (54.5) 60 (5.6) 5 (0.5) 1988 10.2 (5.5-10.6) 8688 
Study6 aduits aged ;,:60 y 
!rom primary care 
practice in 
Birmingham, 
England 
EPIC-Norfolk Adults living ln 12341 58 (40-78) 6596 (53.4) 360 (2.9) NA 1995·1998 13.4 (12.6-14.3) 158227 
Study" Norfolk, England 
HUNT Study27 Adults living in 24291 55 (41-98) 16 506 (68.0) 381 (1.6) NA 1995-1997 8.3 (7 .9-8.9) 197935 
Nord-Trondelag 
County, Norway 
Le id en Ali adults aged 85 y 470 85 301 (64.0) 20 (4.3) 12 (2.6) 1997-1999 5.2 (2.6-8.5) 2650 
85-Plus living in lelden, 
Study7 the Netherlands 
Pisa cohort8 Patients admitted ta 2903 63 (19-92) 927 (31.9) 208 (7.2) 0 2000-2005 2.6 (1.6-3.8) 7966 
the cardiology 
department ln 
Pisa, ltaly 6 
1891 (4Ù.7) SHIP39 Adults living ln 3883 49 (20-81) 934 (24.1) 140 (3.6) 1997-2001 10.1 (9.3-10.7) 37 532 
Western 
Pomeranla, 
Germany 
Australia 
Busselton Adults living ln 1950 51 (18-90) 933 (47.8) 49 (2.5) 12 (0.6) 1981 20.0 (20.0-20.0) 34676 
Health Busselton, 
Study22 Western Australia 
South America 
Brazilian Adults of Japanese 980 57 (30-92) 510 (52.0) 90 (9.2) NA 1999-2000 7.3 (7.0-7.5) 6877 
Thyroid descent living ln 
Study4° Sao Paulo, Brazil 
Ove ra li 52674 59 (18-100) 30 828 (58.5) 2188 (4.2) 269 (0.5) 1981-2005 8.8 (7.9-12.4) 501922 
Abbreviations: EPIC, European Prospective Investigation of Cancer; Health ABC Study, Health Aging and Body Composition Study; HUNT, Nord-Trondelag Health 
Study; IQR, interquartile range (25th-75th percentiles); NA, data not available; SHIP, Study of Health in Pomerania. 
a Participants younger than 18 years were excluded. 
bwe used a comrnon definition of subclinical hyperthyroidism, thyrotropin level lower than 0.45 mlU/L, and normal free thyroxine level, whereas thyrotropin 
cutoff values varied among the previous reports from each cohort, resulting in different numbers frorn previous reports. For endogenous subclinical 
hyperthyroidism, 216 participants of Health ABC Study, 9 of Leiden 85-Plus Study, 258 of SHIP, and 14 of Busselton Health Study were exciuded because of 
thyroid medication use al baseline. · 
coata on thyroid medication use (thyroxine, antithyroid drugs) were not available for 8 participants of the Health ABC Study al baseline, for 1006 participants of 
Birmingham Study du ring follow-up, and for ail participants du ring follow-up in EPIC-Norfolk Study, HUNT Study, and Brazilian Thyroid Study. 
dFor ail cohorts, we used the maximal follow-up data Illat were available, which might differ from previous reports for some cohorts. 
6Patients with acute coronary syndrome or severe illness were excluded from the Pisa cohort. 
which were insufficiently sensitive for the diagnosis of 
subclinical hyperthyroidism. After the exclusion of us-
ers of thyroxine and antithyroid drugs, the final sample 
comprised 10 prospective cohorts with a total of 52 674 
participants (median age, 59 years, 58.5% women), with 
median follow-up 8.8 years and total follow-up 501 922 
persons-years. Of the participants, 50 486 were euthy-
roid and 2188 (4.2%) had endogenous subclinical hy-
perthyroidism (Table 'I ), including 1884 participants 
(3.6%) with low but not suppressed thyrotropin (0.10-
0.44 mIU/L) and 304 (0.6%) with suppressed thyrotro-
pin ( <0.10 mIU/L). The loss to follow-up rate was lower 
than 5% in all included studies. Total and CHD mortal-
ity were reported in all cohorts. Coronary heart disease 
event data were available for 22 437 participants from 6 
cohorts (3.2% with subclinical hyperthyroidism), and 
were formally adjudicated for 4 of these 6 studies.7·8.io.33 
After excluding those with AF at baseline, data for inci-
dent AF events were available in 8711 participants from 
5 cohorts (9.3% with subclinical hyperthyroidism). 
During follow-up, 8527 participants died (including 
1896 from CHD), 3653 had CHD events, and 785 had 
incident AF. ln age- and sex-adjusted analyses, the over-
all HR for participants with subclinical hyperthyroid-
ARCH !NTERN MED/VOL 172 (N0.10), MAY 28, 2012 
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Euthyroidism Subclinical Hyperthyroidism 
Events, Participants, Events, Participants, 
Source No. No. No. No. HR (95% Cl) Weight, % 
Total mortality 
Cardiovascular Health Study 10 1525 2526 26 43 1.04 (0.70-1.53) 9.6 
Health, Aging and Body Composition Study'" 611 2169 14 43 1.25 (0.73-2.12) 6.6 
Birmingham StudY" 440 1015 29 60 1.39 (0.95-2.02) 10.2 
EPIC-Norfolk Study" 1925 11981 62 360 1.05 (0.82-1.36) 14.6 
HUNT Study" 2170 23910 57 381 1.52 (1.16-1.97) 14.2 
Leiden 85-Plus Study7 402 450 20 20 1.49 (0.95-2.32) 8.4 
Pisa cohort" 247 2695 21 208 1.12 (0.71-1.74) 8.3 
SHIP39 276 2949 143 934 0.99 (0.81-1.21) 16.7 
Busselton Health Study22 478 1901 11 49 1.03 (0.57-1.88) 5.6 
Brazilian Thyroid Study40 55 890 15 90 2.73 (1.53-4.88) 5.8 
Total (1'=49%) 6129 50466 398 2168 • 1.24 (1.06-1.46) 100.0 0.2 0.5 1.0 2.0 5.0 
CHD mortality1• 
Cardiovascular Health Study10 367 2526 43 1.35 (0.67-2.72) 11.0 
Health, Aging and Body Composition Study" 145 2159 43 0.76 (0.19-3.09) 2.8 
Birmingham StudY" 114 1013 8 59 1.50 (0.73-3.09) 10.5 
EPIC-Norfolk Study23 484 11981 17 360 1.24 (0.77-2.02) 23.1 
HUNT Study27 376 23910 381 0.95 (0.42-2.13) 8.4 
Leiden 85-Plus Study7 41 445 20 0.65 (0.09-4.74) 1.4 
Pisa cohort' 96 2695 14 208 1.93 (1.10-3.40) 17.0 
SHIP39 37 2941 22 925 1.08 (0.64-1.84) 19.4 
Busselton Health Study22 144 1898 3 49 0.91 (0.29-2.85) 4.2 
Brazilian Thyroid Study'° 888 89 2.35 (0.50-11.14) 2.3 
Total (1'=0%) 1813 50456 83 2177 1.29 (1.02-1.62) 100.0 
0.2 0.5 2.0 5.0 
CHO eventst 
Cardiovascular Health Study10 958 2526 17 43 1.12 (0.69-1.81) 16.1 
Health, Aging and Body Composition Study" 441 2169 12 43 1.59 (0.90-2.83) 11.2 
EPIC-Norfolk Study23 1562 11981 50 360 1.12 (0.85-1.49) 46.7 
Leiden 85-Plus Study7 75 448 20 1.37 (0.50-3.74) 3.7 
Pisa cohort" 153 2695 16 208 1.33 (0.79-2.22) 13.9 
Busselton Health Study22 356 1895 9 49 1.15 (0.59-2.24) 8.5 
Total (12=0%) 3545 21714 186 723 1.21 (0.99-1.46) 100.0 
0.2 5.0 
Incident atrial fibrillation 
Cardiovascular Health Study10 662 2477 19 42 Ill 1.84 (1.17-2.91) 65.4 
Health, Aging and Body Composition Study'" 17 1797 36 1.85 (0.10-34.03) 1.6 
Leiden 85-Plus Study7 39 405 15 0.34 (0.02-5.69) 1.7 
SHIP" 20 2199 14 692 1.38 (0.69-2.78) 28.0 
Busselton Health StudY'' 13 1023 25 2.85 (0.37-21.9) 3.3 
Total (1'=0%) 751 7901 34 810 1.68 (1.16-2.43) 100.0 
0.2 0.5 1.0 2.0 5.0 
Figure. Total mortality, coronary heart disease (CHO) mortality, CHO events, and atrial fibrillation in endogenous subclinical hyperthyroidism vs euthyroidism. Age 
and sex-adjusted hazard ratios (HRs) and their 95% confidence intervals (Gis) are represented by squares or diamonds, those to the right of the solid line indicate 
increased risk. The sizes of data markers are proportional to the inverse of the variance of the HRs. *Forty-one participants were excluded from the analyses of 
CHO mortality because of missing cause of death. tThe Birmingham Study,6 HUNT (Nord-Trondelag Health Study),27 SHIP (Study of Health in Pomerania),39 and 
Brazilian Thyroid Study40 were not included because follow-up data were only available for death. EPIC indicates European Prospective Investigation of Cancer. 
ism compared with euthyroidism was 1.24 (95% CI, 1.06-
1.46; 23.5 vs 19.9/1000 person-years for euthyroidism) 
for total mortality, 1.29 (95% CI, 1.02-1.62; 5.1vs4.5/ 
1000 person-years) for CHD mortality, 1.21 (95% CI, 
0.99-1.46; 24.1 vs 20.9/1000 person-years) for CHD 
events, and 1.68 (95% CI, 1.16-2.43; 17.1vs12.5/1000 
person-years) for incident AF (Figure). Stroke and can-
cer mortality were not higher with subclinical hyperthy-
roidism. Heterogeneitywas present across studies for total 
mortality (12 = 49%), but not for CHD mortality, CHD 
events or incident AF (all I2 = 0%). Among subclinical 
hyperthyroid and euthyroid groups, there was a trend for 
more la te events than early events for total mortality, CHD 
mortality, CHD events, and AF events (for all, P value 
for trend, :S.02). We subsequently examined whether 
heterogeneity was related to differences in risks by de-
gree of subclinical hyperthyroidism and age. 
Table 2 presents stratified analyses for total mortal-
ity, CHD mortality, CHD events, and incident AF. In age-
and sex-adjusted analyses, CHD mortality and incident AF 
(but not other outcomes) were significantly greater in par-
ticipants wi.th lower thyrotropin levels: HRs, 1.24 (95% CI, 
0.96-1.61) and 1.63 (95% CI, 1.10-2.41) for thyrotropin 
levels 0.10-0.44 mlU/L, respectively, vs HRs, 1.84 (95% CI, 
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Table 2. Stratified Analyses for the Association Between Endogenous Subclinical Hyperthyroidism iind the Risk of Total Mortality, 
GHD Mortalily, GHD Events, and Atrial Fibrillation 
Total Mortality CHO Mortalityb 
Events/Participants, No. HR (95% Cl) Events/Participants, No. HR(95% Cl) 
Subclinical Age/ Multivariate Subclinlcal Age/ Multivariate 
Variable Euthyroidism Hyperthyroidism Sex·Adjusted Modela Euthyroidism Hyperthyroidism SeX·Adjusled Modela 
Total population 8129/50486 398/2188 1.24 (1.06-1.46) 1.17 (0.99-i.38) 1813/50456 83/2177 1.29 (1.02-1.62) 1.25 (0.97-1.62) 
Sex 
Men 4156/20887 216/959 1.28 (1.10-1.49) 1.23 (1.05-1.44) 1069/20869 50/952 1.52 (1.12-2.08) 1.49 (1.07-2.08) 
Women 3973/29599 182/1229 1.12 (0.91-1.40) 1.05 (0.81-1.35) 744/29587 33/1225 1.22 (0.86-1.72) 1.14 (0.78-1.68) 
P value for interaction .31 .31 .35 .30 
Age, yC 
18-49 254/13 819 15/587 1.55 (0.90-2,67) 1.70 (0.98-2.96) 31/13817 3/587 5.01 (1.55-16.19) 4.24 (1.09-16.42) 
50-64 12101118eoct 541729d 1.29 (0.87~1.91) 1.24 (0.85-1.80) 236/17 885ct 71728d 1.08 (0.52-2.23) 1.02 (0.47-2.18) 
65-79 5101/16505 262/797 i .25 (1.04-1 .50) i.i 2 (0.96-1.32) 1254/16487 65/7a7 1.45 (1.11-1.89) 1.40 (1.05-1.88) 
2'80 1561/2268 57175 1.23 (0.94-t61) 1.14 (0.85-1.52) 292/2236d 8f73d 1.16 (0.58-2.30) 0.79 (0.34-1.84) 
P value for trend .45 .18 .05 .06 
Race 0 
White 7221/47 492 344/2015 1.15 (1.00-1.31) 1.10 (0.98-1.24) 1593/47 471 72/2006 1.26 (0.98-1.62) 1.26 (0.9H63) 
Black 413/1089 10/23 1.65 (0.72-3.80) 1.30 (0.69~2.45) 97/1084 1/23 0.96 (0.18-5.11) 0.68 (0.12-3.79) 
Aslan 55/890 15/90 2.73 (1.53-4.88) 2.57 (1.43-4.62) 9/888 2/89 2.35 (0.50-11.14) 2.08 (0.43-10.09) 
P for Interaction .40 .61 .75 .49 
Thyrotropln 
0.45-4:49 mlU/L 8129/50486 1 [Reference] 1 [Reference] 1813/50456 1 [Reference] 1 [Reference] 
0.10-0.44 mlU/L 335/1884 1.23 (1.04-1.45) 1.19 (1.00-1.41) 68/1875 1.24 (0.96-1.61) 1.27 (0.97-1.67) 
<0.10 mlU/L 63(304 1.24 (0.90-1.71) 1.06 (0.72-1.56) 15(302 1.84 (1.12-3.00) 1.53 (0.85-2.77) 
P value for trend .19 .77 .02 .16 
Preexlstlng GVD f 
None 6361/45 505 296/1880 1.26 (1.0H.58) 1.19 (0.97-1.45) 1229/45481 52/1872 1.25 (0.93-1.69) 1.27 (0.94-1.72) 
Yes 1315/3933 72/247 1.28 (0.9H70) 1.14 (0.82-1.59) 466/3929 23/245 1.54 (1.00-2.39) 1.49 (0.91-2.44) 
P value for Interaction .93 .83 .44 .59 
CHO Evenlsg Incident AFh 
Total population 3545/21714 108/723 1.21 (0.99-1.46) 1.22 (1.00-1.48) 751/7901 34/810 1.68 (1.16-2.43) 1.71 (i.18-2.48) 
Sex 
Men 2181/10792 49/313 1.10 (0.83-1.47) 1.08 (0.80-1.45) 376/3689 19/404 1.79 (1.10-2.91) 1.96 (1.19-3.21) 
Women 1364/10 922 59/410 1.38 (1.06-1.79) 1.42 (1.09'1.85) 375/4212 15/406 1.71 (0.98-2.96) 1.61 (0.92-2.81) 
P value for Interaction .25 .18 .90 .61 
Age, yc 
18-49 114/4112 6/122 2.49 (0.46-13.44) 2.41 (0.43-13.46) 2/1261 d 1;259d 1:48 (0.13-16.90) 1.19 (0.06-23.40) 
50-64 816/7344d 18/261 d 0.78 (0.49-1.26) o.81 (0.5H29) 15/966d 5;249d 2.12 (0.44-10.26) 2.25 (0.49-10.35) 
65-79 2362/9286 771305 1.41 (1.12-1.77) 1.38 (1.09-1.74) 595/4284 23/249 1.80 (1.15-2,83) 1.79 (1.13-2.84) 
2'80 253/968 7/35 1.00 (0.49-2.03) 1.06 (0.52-2.19) 138/713d 5;24d 1.35 (0.42-4.35) 1.11 (0.45-2.70) 
P value for trend .45 •. 50 .92 .93 
Race 0 
White 3305/20625 102/700 1.19 (0.98'.1.46) 1.21 (0.99-1.49) 72717013 34/790 1.69 (1.17-2.45) 1.74 (1.20-2.52) 
Black 240/1089 6/23 1.52 (0.69-3.32) 1.43 (0.65-3.16) 24/888 0120 NA NA 
Asian NA NA NA NA NA NA NA NA 
P value for interaction .56 .69 NA NA 
Thyrotropln 
0.45-4.49 mlU/L 3545/21714 1 [Reference] 1 [Reference] 751/7901 1 [Reference) 1 [Reference] 
0.10-0.44 mlU/L 89/572 .1.27 (1.03-1.58) 1.29 (1.04-1.62) 30/735 1.63 (1.10-2.41) 1.70 (1.15-2.53) 
<0.10 mlU/L 19/151 1.08 (0.69-1.69) 1.13 (0.7H79) "4175 2.54 (1.08-5.99) 2.34 (0.98,5.58) 
P value for trend .74 .61 .03 .06 
Preexistlng GVD9 
None 2492/18022 79/554 1.32 (1.05-1.65) 1.32 (1.05-1.66) 545/6633 271746 1.78 (1.16-2.74) 1.78 (1.16-2.75) 
Yes 1044/3661 29/168 1.06 (0.73-1.54) 1.15 (O. 78-1.68) 20111205d 7;54d 1.44 (0.46-4.58) d 2.05 (0.98-4.32) d 
P value for interaction .33 .55 .73 .75 
Abbreviations: AF, atrial fibrillation; CHD, coronary heart dlsease; CVD, cardiovascular disease; HR, hazard ratio; NA, data not applicable. 
aAdjusted for age, sex, systolic blood pressure, current and former smoking, total cholesterol, and diabetes at baseline. The Birmingham Study was not 
inciuded in thls analysis because of lack of data on cardiovascular rlsk factors. 
bforty-one participants were excluded !rom the analyses of CHO mortality because of missing cause of death. 
"These HRs were adjusted for sex and age as a contlnuous variable Io avold resldual confounding wlthln age strata. 
d Sorne strata from specific studles were excluded when there was no event ln a subgroup. 
"Data on race were not avallable for the Birmingham study (n = 1075). The Asian group was only !rom the Brazllian (of Japanese descent) Thyroid Study. 
roata on previous CVD were no! avallable for the Birmingham study (n = 1075) and for 34 participants of EPIC (European Prospective Investigation of 
Cancer)-Norfolk Study, Leiden 85-Plus Study, and Busselton Health Study. For analysis of CHO eve11ls, 32 participants of EPIC-Norfolk Study and Busselton 
Health Study were excluded for the same reason. 
gThe Birmingham Study, HUNT Study (Nord-Trondelag Health Study), SHIP (Study of Health in Pomerania), and Brazllian Thyrold Study were not included 
because follow-up data were only avallable for death. 
h Participants with preexistlng AF at baseline or missing data on AF du ring follow-up were excluded: CHS (Cardiovascular Health Study), 50 and 0, respectlvely; 
Health ABC (Aging and Body Composition) Study, 38 and 341, respectively; Leiden-85-Plus Study, 48 and 2 respectively; SHIP, 44 and 948, respectively; and 
Busselton Health Study, 11 and 891, respectively. 
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Table 3. Sensilivity Analyses of the Association Between Subclinical Hyperthyroidism and the Risk of Total Mortality, GHD Mortality, 
GHD Events, and Atrial Fibrillation 
Total Mortalily CHO Mortality 
Events/Participants, No. Events/Participants, No. 
Subclinical Subclinical 
Variable Euthyroidism Hyperthyroidism HR (95% Cl) Euthyroidism Hyperthyroidism HR (95% Cl) 
Ali eligible studies 
Random-effects model 8129/50486 398/2188 
Fixed-effects model 8129/50486 398/2188 
Definition of subclinical hyperthyroidism 
Excluding those with missing FT,a 8129/50486 331/1838 
Excluding those with abnormal free or total T3b 8129/50486 353/2045 
Thyrold medication use 0 ' 
lncluding ail regardless ofthyroid medication used 8198/50835 424/2336 
Excluding thyroid medication users at basèllne or 8079/50281 385/2124 
during follow-up 
Excluding users of thyroid medication and other 8045/50161 376/2096 
medications that cou Id alter thyrotropin and/or 
FT4levels 0 
Outcomes 
Exclu ding sofl CHD outcomes t NA NA 
Only studles with formai adjudication proceduresg NA NA 
HR calculated until 5 y of follow-uph 2972/50486 184/2188 
Excluding studies 
Excluding study of cardlac patients' 7882/47791 377/1980 
Excluding study with recent ladine 7853/47537 255/1254 
supplementation39 
Excluding study inconsistent wlth proportional 7689/49471 369/2128 
hazard assumption6 
Excluding small study because of potential 8074/49596 383/2098 
publication bias40 
Further adjustments of multivariate models 
Plus lipid-lowerJng and antihypertenslve 5696/37149 302/1738 
medications 1 
Plus BMIÎ 7406/48500 354/2069 
1.12-3.00) and 2.54 (95% CI, 1.08-5.99) for thyrotropin 
levels lower than 0.10 mIU/L, respectively (for bath, P value 
for trend, :'S.03 for each outcome). Men hada slightly greater 
risk for total mortality, CHO mortality and incident AF, 
withoutstatistical significance for interaction (all P 2: .30). 
Risks for Asian participants were greater for total mortal-
ity (HR, 2. 73; 95% CI, 1.53-4.88) and CHO mortality (HR, 
2.35; 95% CI, 0.50-11.14), with nonsignificant interac-
tion test results (all P 2: .40), but data on Asian partici-
pants were available from only 1 cohort.10 Risks die! not 
differ significantly by age or preexisting CVD. All risks were 
similar after further acljustment for carcliovascular risk fac-
tors, with an attributable risk of 14.5% for total mortality 
to 41.5% for AF in those with subclinical hyperthyroicl-
ism and a population attributable risk ofO. 7% for total mor-
tality to 6.2% for AF, given the relatively low prevalence 
of subclinical hyperthyroiclism. 
Sensitivity analyses yielded similar results (Table 3). 
Excluding users of thyroxine and antithyroid drugs clur-
ing follow-up or adcling participants taking the.se medica-
tions at baseline to the overall sample yielded similar HRs. 
The risk of CHO mortality was higher (HR, 1.50; 95% CI, 
1.00-2.27) after limiting the analyses to 4 studies with for-
mal adjudication procedures. 7•8•13•38 Risks of total mortal-
ity, CHO mortality and incident AF increased slightly af-
ter excluding a study with previous iodine 
supplementation.39 Risks were similar after further acljust-
ment of multivariate moclels with lipid-lowering and an-
tihypertensive medication use or body mass index. 
1.24 (1.06-i .46) 1813/50456 83/2177 1.29 (1.02-1.62) 
1.19 (1.07-1.33) 1813/50456 83/2177 1.29 (1.02-1.62) 
1.29 (1.07-1.56) 1813/50456 72/1827 1.36 (1.06-1.75) 
1.20 (1.01-i.43) 1813/50456 75/2036 1.25 (0.98-1.60) 
i .22 (1.05-1.42) 1830/50 803 86/2322 1.26 (i .00-1.58) 
1.25 (1.07-1.47) 1799/50252 81/2114 1.32 (1.04-1.67) 
1.25 (1.07-1.47) 1792/50132 79/2086 1.31 (1.03-1.66) 
NA NA NA NA 
NA 649/7825 25/314 1.50 (1.00-2.27) 
1.40 (1.13-1.73) 698/50456 43/2177 1.61 (1.16-2.22) 
1.26 (1.06-1.51) 1717/47761 69/1969 1.18 (0.91-i.53) 
1.30 (1.10-1.54) 1776/47 515 61/1252 1.34 (1.03-1.74) 
1.23 (1.03-1.47) 1699/49443 75/2118 1.26 (0.99-1.61) 
1.17 (1.03-1.32) 1804/49 568 81/2088 1.27 (1.00-1.60) 
1.20 (1.00-1.45) 1200/37122 56/1728 1.26 (0.94-1.69) 
1.17 (0.99-1.38) 1635/48 473 70/2059 1.25 (0.96-1.61) 
(continued) 
The proportional hazard assumption was consistent 
across studies, except for the Birmingham Study6 
(P = .009), which was excluded in a sensitivity analysis 
giving similar results. We found limitecl evidence of pub-
licatiop. bias with visual assessment of age- and sex-
acljusted funnel plots and the Egger test for total mor-
tality (P = .17), but not the other outcomes (allP 2: .20). 
For total mortality, the Brazilian Thyroid Study10 might 
be an outlier with no corresponding study of similar size 
with reduced risk associated with subclinical hyperthy-
roidism: a sensitivity analysis excluding this stuclyyieldecl 
similar results. 
In this analysis of all available prospective cohorts, en-
dogenous subclinical hyperthyroiclism was associated with 
an increasecl risk of total mortality, CHO mortality, and 
incident AF. Coronary heart clisease mortality and inci-
dent AF (but not other outcomes) were significantly 
greater in participants with thyrotropin levels lower than 
0.10 mIU/L than those with thyrotropin levels between 
0.10 and 0.44 mIU/L (for both, P value for trend, :'S.03). 
Risks did not differ significantly by age, sex, or preex-
isting CVO and were similar after further adjustment for 
carcliovascular risk factors. 
Previous study-level meta-analyses procluced conflict-
ing results regarding the association between subclinical 
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Table 3. Sensitivity Analyses of the Association Between Subclinical Hyperthyroidism and the Risk of Total Mortality, CHO Mortalily, 
CHO Events, and Atrial Fibrillation (conlinued) 
CHD Events lncidentAF 
Events/Participants, No. Events/Participants, No. 
Subclinical Subclinical 
Variable Euthyroidism Hyperthyroidism HR (95%CI) Euthyroidism Hyperthyroidism HR (95% Cl) 
Ali eligib/e studies 
Random-effects mode! 3545(21714 108/723 1.21 (0.99-1.46) 751/7901 34/810 1.68 (1.16-2.43) 
Fixed-effects model 3545/21714 1081723 1.21 (0.99-1.46) 751/7901 34/810 1.68 (1.16-2.43) 
Oefinition of subclinical hyperthyroidism 
Excluding those with mlssing FTl 3545/21714 85/660 1.16 (0.93-1.44) 751/7901 19/750 i.73 (1.19-2.50) 
Excluding th ose wîth abnormal free or total T, b 3545/21714 99/652 1.19 (0.98-1.46) 75117901 34/763 1.64 (1.14-2.35) 
Thyroid medication use0 
lncluding ail regardless ofthyroid medication used 3585/21907 1111769 1.12 (0.93-1.36) 758/8175 35/930 1.54 (1.07-2.22) 
Excluding thyroid medication users at baseline or 3515/21608 103/705 
du ring follow-up 
1.20 (0.98-1.46) 73517707 30/755 1.62 (1.09-2.39) 
Excluding users of thyroid medication and other 3504/21548 103/704 1.20 (0.99-1.47) 733/7609 29/734 1.62 (1.09-2.41) 
medications that could alter thyrotropin and/or 
Fî4 leve1se 
Outcomes 
Exclu ding sofl CHO outcomes f 2934/21714 991723 1.28 (1.04-1.56) NA NA NA 
On/y stud/es with formai adjudication procedures9 162717838 49/314 1.31 (0.98-1.74) NA NA NA 
HR calculated until 5 y of follow-up h 1585/21714 571723 1.26 (0.96-1.64) 257/6878 13/785 1.60 (0.87-2.95) 
Excluding studies 
Excluding study of cardiac patients' 3392/19019 92/515 i.19 (0.97-1.46) NA NA NA 
Excluding study with recent iodine 
supplementation39 
NA NA NA 731/5702 20/118 1.81 (i.17-2.79) 
Excluding study inconsistent with proportional NA NA NA NA NA NA 
hazard assumption6 
Excluding small study because of potential NA NA NA NA NA NA 
publication bias40 
Further adjustments of multivariate models 
Plus llpid-lowerjng and antlhypertensive 1962/9493 56/337 
medications1 
1.28 (0.98-1.$8) 74717850 34/805 1.71 (1.18-2.48) 
Plus BMli 3440/20941 102/671 1.23 {1.0H.50) 745/7843 34/803 1.68 (1.16-2.43) 
Abbreviations: BMI, body mass index; CHO, coronary heart disease; FT4, free thyroxine; HR, hazard ratio {all age and sex adjusted, except the last 2 rows); 
NA, data not applicable; T,, triiodothyronine. 
aA total of 350 participants were excluded in this analysis: CHS (Cardiovascular Health Study), 33; Health ABC (Aging and Body Composition), 29; HUNT Study 
(Nord-Trondelag Health Study), 285; SHIP {Study of Health in Pomerania), 2; and Busselton Health Study, 1. 
b A total of 116 participants with subclinical hyperthyroidism and ab normal free T3 were excluded in this analysis: Birmingham Study, 4; Leiden 85-Plus Study, 
18; Pisa cohort, 53; and SHIP, 41. Twenty-seven participants !rom the HUNT Study with subclinical hyperthyroidism and abnormal total T, level (not measured in 
other studies) were also excluded. 
"The numbers of thyroid medication users (ie, thyroxine, antithyroid drugs) during follow-up are given in Table 1. 
dA total of 497 thyroid medication users (ie, thyroxine, antithyroid drugs) at baseline were added to the overall sample in this sensitivity analysis. 
e ln addition to the 269 thyroid medication users du ring follow-up, 148 users of other medications that could alter thyrotropin and/or FT, levels (ie, corticoids, 
amiodarone, iodine1·3•10) were excluded when data were available (CHS, O; Health ABC Study, 61; SHIP, 87; and Busselton Health Study, 0). 
Isolt CHO outcomes were defined as hospitalization for angina or revascularization (coronary angioplasty or surgery), and participants with these outcomes 
were excluded !rom this analysis, which were available separately in 3 studies.7•10·38 ln contras!, hard outcomes were defined as nonfatal myocardial infarction or 
CHO death, as defined in the current Framingham risk score." 
g Formai adjudication procedures were defined as having clear criteria for the outcomes that were reviewed by experts for each potential case, which was 
possible in 4 studies.7·6·10·38 For this analysis, CHO adjudication based only on death certificates was not considered as a formai adjudication procedure. 
h Hazard ratios calculated until 5 years of follow-up were not statistically significantly different !rom those calculated over complete follow-up data (all P > .25). 
For AF events, the HR until 5 years of follow-up was reduced, likely because of lower power (13 events in subclinical hyperthyroidism instead of 34 over complete 
follow-up). The HR for AF events became statistically significant with inclusion of later events, and we found a time interaction for AF events {P value for 
interaction, .003): rates of AF became higher alter 3 years and further increased with additional follow-up data. 
iAll participants of the Birmingham Study and EPIC (European Prospective Investigation of Cancer)-Norfolk Study were excluded tram these analyses because 
of lack of data on lipid-lowering and antihypertensive medications, as well as some participants !rom other cohorts. 
IAll participants of the Birmingham Study were excluded !rom these analyses because of lack of data on BMI, as well as some participants from other cohorts. 
hyperthyroidism and cardiovascular mortality. 15-17 Our re-
sults, based on individual participant data, demonstrate that 
there is indeed an increasecl risk of total and CHD mortal-
ity associated with subclinical hyperthyroidism, 15·16 and aclcl 
new information on subgroups at increased risk and the 
risk of incident AF. Previous meta-analyses could not ac-
curately assess the differences in risk according to thyro-
tropin level, because of potential ecological fallacy with-
out individual participant data analysis18 and they pooled 
indiviclual studies using varying thyrotropin cutofflevels, 
outcome definitions, and confounding factors for adjust-
ment.15·16 Only a few individual studies reported stratified 
risks accorcling to thyrotropin levels. Our results are con-
sistent with those recently reported by Vacliveloo et al,41 
who found an increased risk ofnonfatal CVD, increasing 
with lower thyrotropin levels (HR, 1.67 (95% CI, 1.45-
1.92) for thyrotropin level 0.10-0.40 mlU/L, vs HR, 1.74 
(95% CI, 1.36-2.21] for thyrotropin level <0.10 mIU/L); 
this study was not inclucled in our analysis because of its 
retrospective case-control design. 
To our knowledge, no meta-analysis has been con-
clucted on the association of AF with subclinical hyper-
thyroidism. Similar to our data, some individual stuclies 
showed increased risk of AF associatecl with subclinical 
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hyperthyroidism.9•10 Sawin et al9 reported an increased 
risk of incident AF in persons older than 60 years with 
thyrotropin levels lower than 0.1 mlU!L (HR, 3.8; 95% 
CI, 1. 7-8.3) and among those with thyrotropin levels be-
tween 0.1and0.4 mIU!L (HR, 1.6; 95% CI, 1.0-2.5); this 
study was excluded from our analysis because of its first-
generation thyrotropin assay. 26 Cappola et a!1° showed a 
relationship between low thyrotropin levels and AF in-
cidence in individuals 65 years or older with endoge-
nous subclinical hyperthyroidism, which was also sig-
nificant in those with thyrotropin levels between 0.10 and 
0.44 mlU!L (HR, 1.85; 95% CI, 1.14-3.00). In a popula-
tion with a mean age of 65.5 years, Vadiveloo et al41 found 
an increased risk of cardiac arrhythmia for participants 
with endogenous subclinical hyperthyroidism, espe-
cially in those with thyrotropin levels lower than 0.10 
mIU!L. Taken together, these previous studies and our 
data suggest that the risk of AF in individuals with en-
dogenous subclinical hyperthyroiclism is higher with lower 
thyrotropin levels and is mostly pronouncecl in those with 
thyrotropin levels lower than 0.10 mIU!L. 
The increased risks of AF events and total and CHD 
mortality associatecl with subclinical hyperthyroidism have 
been postulated to be causecl by systemic effects of thy-
roid hormones, su ch as a change in carcliac fonction 1·3 
or carcliac arrhythmia.3·42 These hypotheses are favorecl 
by the fact that acljustment for carcliovascular risk fac-
tors clic! not alter risks of subclinical hyperthyroidism. 
An alternative explanation for the results couic! be pub-
lication bias, selection bias or quality issues in the in-
cluclecl cohorts, or unmeasurecl confounclersY Sensitiv-
ity analyses (1) exclucling a small stucly40 with no 
corresponcling stucly of similar size with reclucecl risk as-
sociatecl with subclinical hyperthyroiclism and (2) pool-
ing only higher-quality cohorts yielclecl similar results. 
Among the strengths of our stucly, an incliviclual par-
ticipant data analysis is considerecl the best way for syn-
thesizing eviclence across several studies because it is not 
subject to potential bias from stucly-level meta-analyses 
(ecological fallacy) 18 and allows performance of time-to-
event analyses and use of standarclized clefinitions of pre-
dictors, outcomes, and acljustment for confounding fac-
tors.19 We incluclecl all available international publishecl 
data after conclucting a systematic review. 
Among the limitations of our stucly, our analysis in-
clucled predominantly white populations, except for one 
cohort inclucling Brazilians of japanese descent.40 Al-
though we incluclecl ail available data, our results may 
not be generalizecl to all other populations. Second, thy-
roicl fonction tests were performecl only at baseline, and 
we have no data to assess how many participants with 
subclinical hyperthyroiclism progressecl to overt hyper-
thyroidism or normalizecl to euthyroiclism over time, 
which is a limitation of most publishecl large co-
horts.10·23·27·38 Thircl, subclinical hyperthyroiclism was cle-
finecl as a thyrotropin level lower than 0.45 mIU!L and 
normal FT4 levels, since T3 was not measurecl in all in-
cludecl cohorts; sensitivity analyses exclucling partici-
pants with abnormal total or free T3 levels yielcled simi-
lar results. Fourth, the high prevalence of subclinical 
hyperthyroiclism in the Stucly of Health in Pomerania 
(SHIP, Northern Germany, 24.l %).may be explainecl by 
the iodine supplementation that was introducecl in the 
area 4 years before the start of SHIP in the late 1990s:H 
Exclucling SHIP yielclecl similar risk estima tes. Fifth, we 
dicl not have information on the etiology of subclinical 
hyperthyroiclism, while carcliovascular complications may 
be relatecl to the etiology of the conclition.45 Sixth, up to 
2.6% of participants startecl thyroxine or antithyroicl clrugs 
during follow-up; sensitivity analyses exclucling users of 
these meclications cluring follow-up yielclecl similar re-
sults. However, we clic! not have complete data from ail 
cohorts on use of other meclications that couic! alter thy-
rotropin and/or FT4 levels, such as steroicls or amioda-
rone; sensitivity analyses exclucling other meclications us-
ers (0%-2.8% when available) yieldecl similar results. 
Seventh, only mortality and carcliovascular outcomes were 
assessecl. Other conditions such as osteoporosis and cog-
nition were not analyzed and couic! partly account for 
increasecl total mortality, particularly among elclerly per-
sons, although data on the associations between sub-
clinical hyperthyroiclism and osteoporosis and cogni-
tion are conflicting.1 Eighth, 4 of 6 stuclies7·8·10·38 formally 
acljuclicatecl CHD outcomes. Sensitivity analyses lim-
itecl to these 4 studies yielclecl similar risk estimates. As 
most includecl cohorts usecl self-reportecl preexisting CVD, 
stratifiecl analyses accorcling to preexisting CVD shoulcl 
be interpretecl with caution. 
Recent guiclelines4 recommencl that "treatment of 
SH [subclinical hyperthyroiclism] shoulcl be strongly 
consiclerecl in all indivicluals 2:65 years of age" with 
thyrotropin level lower than 0.10 mIU!L (recommen-
clation 65) and "treatment of SH should be consiclerecl 
in inclividuals 2:65 years of age" with low thyrotropin 
levels but 0.1 mIU!L or higher (recommenclation 66). 
Based on all available prospective cohort stuclies, our 
finclings of increasecl risks of total mortality, CHD 
mortality, and incident AF associated with subclinical 
hyperthyroiclism, with greater risks of CHD mortality 
and AF among those with thyrotropin levels lower 
than 0.10 mIU/L, are consistent with these recent 
guiclelines.4 However, findings basecl on observational 
data shoulcl be interpretecl with great caution for clini-
cal practice, since they are subject to several aforemen-
tioned limitations. No clinical trials have assessecl 
whether treating subclinical hyperthyroiclism results 
in improvecl carcliovascular outcomes. Because our 
data incluclecl only a limited sample of young men and 
premenopausal women, generalization of our finclings 
to younger aclults is limitecl. 
In conclusion, pooling incliviclual data from ail avail-
able prospective cohorts suggests that enclogenous sub-
clinical hyperthyroiclism is associatecl with an increased 
risk of total mortality, CHD mortality, and incident AF, 
with higher risks of CHD mortality and AF with thyro-
tropin levels below 0.10 mIU!L. Our stucly is observa-
tional, and as such cannot address whether the risks as-
sociatecl with subclinical hyperthyroiclism are lowerecl 
by treatment. A large ranclomizecl controlled trial with 
relevant clinical outcomes will be requirecl to clemon-
strate whether these risks are alterecl by therapy; such a 
trial will be challenging to concluct given the large sample 
size requirecl and the lower prevalence of aclults with sub-
clinical hyperthyroiclism comparecl with subclinical hy-
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pothyroidism. If conducted, such a trial should exam-
ine prevention of AF and surrogate outcome measures, 
such as carotid intima-media thickness.46 
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